The “Acute Myeloid Leukemia Therapeutics Market”
analyzes and studies the major market drivers, restraints, and
opportunities in regions such as North America, Europe, and Japan.
Browse market data tables and in-depth TOC on Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 – 2020).
http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html
Early buyers will receive 10% customization on reports.
http://www.marketsandmarkets.com/Market-Reports/acute-myeloid-leukemia-therapeutics-market-526.html
Early buyers will receive 10% customization on reports.
Acute myeloid leukemia is also known as acute
myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic
leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia,
there is a rapid production of abnormal white blood cells that get
collected in the bone marrow and disturb the production of normal blood
cells. White blood cells guard the body from infections caused by
bacteria. Acute myeloid leukemia is divided into childhood acute myeloid
leukemia and adult acute myeloid leukemia.
Acute myeloid leukemia has several subtypes;
treatment and prognosis varies among subtypes. Five-year survival varies
from 15–70%, and relapse rate varies from 33-78%, depending on subtype.
AML is treated initially with chemotherapy aimed at inducing a
remission; patients may go on to receive additional chemotherapy or a
hematopoietic stem cell transplant. Recent research into the genetics of
AML has resulted in the availability of tests that can predict which
drug or drugs may work best for a particular patient, as well as how
long that patient is likely to survive.
The acute myeloid leukemia therapeutics market in G8
countries was valued at $216 million in 2010 and is expected to grow at a
CAGR of 28.40% from 2015 to 2020. The market was dominated by AVD
regimen in 2010. AVD regimen accounted for the largest share; i.e.
54.08% of the acute myeloid leukemia therapeutics market in G8 Countries
in 2010. However, in 2020, the market is expected to be dominated by
AVD regimen, Cytarabine drug and Quizartinib molecule, with sales
amounting to $698 million, $285 million, and $234 million respectively.
According to WHO, acute myeloid leukemia is expected
to be more prominent in the developed world due to genetic and
environmental factor, and radiation exposure is the primary cause of all
the types of acute myeloid leukemia. Global incidence of acute myeloid
leukemia was 49,539 in 2008 with the developing countries. Total 62,226
new cases were recorded in 2010 with 95,211 and 129,837 as the predicted
new cases for 2015 and 2020.
The U.S. dominates the leukemia drug market in North
America with a 90.19% share; whereas Germany dominates the market of
Europe with 35.04% share.
The major players in the market include Ambit
Biosciences Corporation (U.S.), Celgene Corporation (U.S.), Cephalon
Inc. (U.S.), Clavis Pharma ASA (Norway), Eisai Co. Ltd (Japan), Genzyme
Corporation (U.S.), and Sunesis Pharmaceuticals Inc. (U.S.).
MarketsandMarkets is a global market research and
consulting company based in the U.S. We publish strategically analyzed
market research reports and serve as a business intelligence partner to
Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports,
company profiles, databases, and custom research services. They cover
thirteen industry verticals, including advanced materials, automotives
and transportation, banking and financial services, biotechnology,
chemicals, consumer goods, energy and power, food and beverages,
industrial automation, medical devices, pharmaceuticals, semiconductor
and electronics, and telecommunications and IT.
We at MarketsandMarkets are inspired to help our
clients grow by providing apt business insight with our huge market
intelligence repository. To know more about us and our reports, please
visit our website www.marketsandmarkets.com
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog
http://www.marketsandmarkets.com
http://twitter.com/marketsmarkets
No comments:
Post a Comment